Pay in 4 interest-free payments of $6.28 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Participants were randomized 1:1 to subcutaneous tirzepatide or semaglutide once weekly, both titrated to maximum tolerated doses over their respective standard schedules, plus a behavioral-support program
10.1080/0886022x.2023.2197075 119 PingG.XiaoyiD.LiliL.HuaX.MaochangL.XinleiG.et al (2021)
Mean weight loss reached 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, compared with 3.1% on placebo
So we have a multiple touchpoint strategy to keep that going
Early evaluation makes treatment more effective and protects against irreversible damage
9 According to Evernorth data in 2023, medical cost savings for plan sponsors totaled $248+ million due to increased diabetes adherence and improved outcomes
US$ 26.81
US$ 21.78
US$ 22.89
US$ 23.74
